Pasithea Therapeutics Corp (KTTA)
$3.89
Performance
- $3.61$4.30$3.89
7.2%
Downside
Day's Volatility :16.05%
Upside
9.53%
- $0.26$12.60$3.89
93.25%
Downside
52 Weeks Volatility :97.92%
Upside
69.13%
Returns
| Period | Pasithea Therapeutics Corp | Index (Russel 2000) |
|---|---|---|
3 Months | -25.18% | 0.0% |
6 Months | -44.13% | 0.0% |
1 Year | -60.06% | 0.0% |
3 Years | -94.12% | -20.6% |
Highlights
Market Capitalization | 4.4M |
Book Value | $15.49 |
Earnings Per Share (EPS) | -14.79 |
Wall Street Target Price | 2.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -37.9% |
Return On Equity TTM | -63.25% |
Revenue TTM | 486.6K |
Revenue Per Share TTM | 0.37 |
Quarterly Revenue Growth YOY | 1498.1% |
Gross Profit TTM | -2.2K |
EBITDA | -16.3M |
Diluted Eps TTM | -14.79 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 48.59%
Technicals Summary
Sell
Neutral
Buy
Pasithea Therapeutics Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Pasithea Therapeutics Corp | -12.71% | -44.13% | -60.06% | -94.12% | -94.12% |
 Regeneron Pharmaceuticals, Inc. | 0.93% | 17.32% | 35.75% | 73.95% | 298.81% |
 Novo Nordisk A/s | 0.96% | -0.08% | 31.44% | 163.47% | 428.79% |
 Alnylam Pharmaceuticals, Inc. | -8.66% | 65.51% | 21.14% | 30.19% | 192.84% |
 Vertex Pharmaceuticals Incorporated | 0.75% | 12.92% | 34.78% | 148.18% | 173.67% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Pasithea Therapeutics Corp | NA | NA | NA | 0.0 | -0.63 | -0.38 | NA | 15.49 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Pasithea Therapeutics Corp | Buy | $4.4M | -94.12% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 298.81% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 428.79% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 192.84% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 173.67% | 32.84 | -4.74% |
Insights on Pasithea Therapeutics Corp
Increasing Revenue
Revenue is up for the last 4 quarters, 13.58K → 976.30K (in $), with an average increase of 59.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -3.86M → -3.86M (in $), with an average decrease of 0.1% per quarter
Vs VRTX
In the last 1 year, Vertex Pharmaceuticals Incorporated has given 36.4% return, outperforming this stock by 97.5%
Institutional Holdings
ADAR1 Capital Management LLC
2.65%Tower Research Capital LLC
0.13%UBS Group AG
0.06%Royal Bank of Canada
0.02%JPMorgan Chase & Co
0.01%
Company Information
Organization | Pasithea Therapeutics Corp |
Employees | 8 |
CEO | Dr. Lawrence Steinman BA, M.D., Ph.D. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$3.89
-8.47%
Keyarch Acquisition Corp
$3.89
-8.47%
Connexa Sports Technologies Inc
$3.89
-8.47%
Us Value Etf
$3.89
-8.47%
First Wave Biopharma Inc
$3.89
-8.47%
Global X Msci Next Emerging
$3.89
-8.47%
Fat Projects Acquisition Corp
$3.89
-8.47%
Capital Link Global Fintech
$3.89
-8.47%
Applied Uv Inc
$3.89
-8.47%